Articles with the keyword: 
Johnson & Johnson to acquire Israel's Omrix for $465 million
piggy submitted, created time 6 days 12 hours (www.reuters.com)
Johnson & Johnson Inc will acquire Israel's Omrix Biopharmaceuticals Inc for $27 a share, or a total of $465 million, the Globes financial news website said on Monday.
Omrix, which makes biosurgical sealants for the prevention of bleeding, or homeostasis, in surgery, is a partner of Johnson & Johnson unit Ethicon.
Ethicon has exclusive sales and marketing rights to Omrix's biosurgical products in the United States and the European Union.
A team from Ethicon was in Israel at the end of last week reviewing the company, the Globes report said 
Industry shifts focus to immunology and cancer
sea-maid submitted, created time 3 weeks 12 hours (www.nature.com)
Economic factors, including competition from generic drugs, is hitting even the big pharmaceutical companies hard, reports Nature. In 2010, Pfizer's Lipitor enters the public domain. For these reasons, the larger companies are narrowing the focus of their research, hitting fewer diseases. They're also working on fewer primary care drugs and more drugs that would be prescribed by specialists, such as cancer drugs.
"When Wyeth Pharmaceuticals announced last week that it would cut some of its research and development (R&D) programs in women's health, the decision seemed counterintuitive
Economics: In defense of Smith--it's not like he didn't warn us
Darkfrog submitted, created time 1 month 1 day (www.nature.com)
I really liked reading this article. Ostensibly, it's about how all the pro economists know that there are flaws in the traditional economic models, but because no one talks about them to intro students or in the media. Even undergraduate economics students are taught the traditional models in their basic classes, but they graduate and go into financial professions without anyone ever mentioning the points at which these models fail to work.
The public is left to assume that the models are wrong and that the economists must have some spooky ulterior motive
Savient shares fall over gout drug safety concerns
sea-maid submitted, created time 1 month 3 days (biz.yahoo.com)
Shares of Savient Pharmaceuticals plunged Monday as Wall Street urged caution over the safety profile of the drug developer's candidate for gout treatment Puricase.
The stock plunged $8.51, or 73.5 percent, to $3.07. Earlier in the session, shares fell to $2.80, their lowest point in more than three years.
On Monday, Savient reported more late-stage study data on Puricase, reinforcing its effectiveness in prior results. If approved, the drug would be administered intravenously, with the goal of removing uric acid from the blood
sea-maid submitted, created time 1 month 3 days (www.fiercebiotech.com)
VioQuest Pharmaceuticalstoday provided a strategic alternatives review and operations update.
sea-maid submitted, created time 1 month 4 days (www.fiercebiotech.com)
Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that it has entered into a letter of intent for a business combination with Medigen Biotechnology Corp. ("Medigen"), a biotech company traded over the bulletin board in Taiwan. In connection with the transaction, Pacgen would acquire all of the issued and outstanding shares of Medigen by way of share purchase or through such other transaction structure as may be determined by the mutual agreement of Medigen and Pacgen
BioTie Therapies Inc. to Acquire Neurology and Immunology Focused Pharmaceutical Company Elbion GmbH
sea-maid submitted, created time 1 month 4 days (www.fiercebiotech.com)
BioTie Therapies has today entered into an agreement to acquire the German pharmaceutical company elbion GmbH. The combination of the two businesses will take place by a share exchange and create a leading European company in the field of discovery and development of therapeutics for central nervous system (addiction, psychotic disorders) and inflammatory diseases (e.g. rheumatoid arthritis, psoriasis and inflammatory diseseas of the respiratory system). elbion GmbH will become a wholly-owned subsidiary of BioTie.
Ark floats gene therapy's boat, for now
sea-maid submitted, created time 1 month 5 days (www.nature.com)
In August, gene therapy's turbulent ride through the clinical rapids took a new twist as Ark Therapeutics released positive top-line results from a phase 3 trial of its adenoviral gene therapy Cerepro (sitimagene ceradenovec) for malignant brain tumors. Although the news boosted the London-based firm's shares, the course to market authorization and registration remains strewn with uncertainty—as Introgen, of Austin, Texas, found, to its cost, when the U.S
Roche confirms Genentech bid, nine-month sales down 2%
sea-maid submitted, created time 1 month 1 week (www.reuters.com)
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG confirmed its commitment to a $43.7 billion bid for the rest of Genentech Inc and reported a two percent fall in nine-month sales to 33.3 billion Swiss francs ($29.26 billion).
Novartis' profit drops 69%; 550 job cuts planned
sea-maid submitted, created time 1 month 1 week (www.fdanews.com)
Swiss drug giant Novartis said Monday that its third-quarter profit dropped 69%, as expenses to buy a stake in eye-care specialist Alcon, higher taxes and last year's gains from selling its Gerber and medical-nutrition business offset growing sales of its cancer and heart drugs.
Scientist Warns Cash Woes "Devastating" to Science
jerry submitted, created time 1 month 2 weeks (www.time.com)
Famed scientist Richard Leakey warned that the worldwide credit crisis will be "just devastating" to scientific research. Two of the major sources of funding, interest from endowments and donations from private companies, are already dropping. The full measure of the problem is expected to become visible in 2009, when organizations plan their budgets.
Repossession "is mental threat"
sea-maid submitted, created time 1 month 3 weeks (news.bbc.co.uk)
Sometimes depression and other mental problems are caused by an inherent imbalance in brain chemistry. We refer to this as clinicl depression. At other times, however, depression is caused by life events. A family member dies, and the patient becomes depressed. It is natural, understandable, and, depending on how the patient manages it, it can be healthy.
So what are the life events most likely to cause this natural depression? House repossession--foreclosure--was rated as one of the top causes, ahead of finding out about infertility
sea-maid submitted, created time 1 month 3 weeks (news.bbc.co.uk)
You know those fluorescent bulbs that save so much energy (and money) and have been promoted by everyone from environmental groups to Wal-Mart? Well they emit UV light.
So should you chuck them in the trash (Oh, this is a BBC article. I'd better say "bin.")? Nope! According to the British Health Protection Agency, being within one foot of an exposed coil is no more dangerous than being outside on a sunny day. Bulbs that are covered up by casings are even less troublesome
Rethinking conservation: Can economics accomplish what environmentalism could not?
sea-maid submitted, created time 1 month 3 weeks (news.bbc.co.uk)
The global economy loses more money from deforestation than the current banking crisis, says an EU-commissioned report. This is taking into account the services that forests perform, such as purifying water and fixing carbon.
This is not a feeble rearrangement of the facts. When we lose the forestland that feeds water to our cities, we need to build our own new reservoirs and purification plants. The article's author, Richard Black of the BBC, wonders if framing conservation in terms of what it can do for human societies will do more good than preserving nature for nature's sake
Africa ill-equipped for fight against cancer
sea-maid submitted, created time 1 month 3 weeks (www.scidev.net)
African governments are ill-prepared to address the continent's growing cancer burden, warn Hany Besadaand and Vadim Ermakov.
abuse@discover8.com
angelfish
jane2007
kavin
Sue Wu
DanyC
addict
siRNA Vector : pRNA-CMV3.1/Neo
www.genscript.com
Arg-Gly-Asp-Ser
R-G-D-S, Arg-Gly-Asp-Ser, supports fibroblast attachment and ...
www.genscript.com
Protein L Resin
Antibody Purification
www.genscript.com
Rabbit Anti Stathmin 1 (Phospho-Ser24) (polyclonal)
antibody : Rabbit Anti Stathmin 1 (Phospho-Ser24) (polyclona ...
www.genscript.com